Ionis Pharmaceuticals is slashing the price of its expected blockbuster drug, Tringolza (olesarsen), in preparation for expanding the drug’s reach with a planned label expansion.
The drug was originally approved for the treatment of familial chylomicronemia syndrome (FCS) in 2024 and launched at an annual list price of $595,000, the company said. Now, Ionis is gearing up to launch services for severe hypertriglyceridemia (sHTG), announcing Wednesday that it is rolling out an updated wholesale purchasing cost (WAC) of $40,000 per year.
The new price point “reflects the substantial value that Olersen can deliver to patients, providers and health systems while supporting timely and sustained patient access,” the company said, adding that the decision was based on “a thorough review of robust provider research and extensive payer engagement.”
Tringorza’s new pricing will take effect April 1 and apply to both its anticipated sHTG indication and its current use in FCS. The FDA is expected to decide on the sHTG application by June 30, and the upfront pricing changes will allow for “aggressive alignment” with payers’ annual contract cycles, while ensuring “seamless launch” and quick access post-approval, the company said.
Insurers’ contract cycles are scheduled to begin in April, allowing Ionis to participate in negotiations and gain “first-mover advantage” in a significant market, Leerink analysts explained in a note to clients, effectively positioning the drug for strong adoption in 2027.
The sharp decline in WAC not only supports broader access and speaks to the rising prices of medicines in the rare disease space, but also could give Ionis an advantage over its market rivals.
The $40,000 price point gives Ionis a price advantage over Arrowhead Pharmaceuticals and competitor Redenpro, which entered the FCS market in November. Redenpro was listed at $60,000 annually prior to negotiations, and Ionis is in a “sweet spot” where he could be “aggressively” signed, Leerink analysts said.
Ionis’ Tringolza has been highlighted by significant hype leading to a potential sHTG launch after William Blair analyst Dr. Miles Minter revealed what he called “best-case scenario” data from the largest sHTG study ever conducted.
In two Phase 3 trials, the drug demonstrated a 55% and 72% placebo-adjusted reduction in triglycerides after 6 months of treatment. Additionally, patients treated in the study had an 85% reduced risk of acute pancreatitis after one year of treatment.
The result exceeded William Blair’s team’s expectations, Minter wrote at the time, but City analysts called it a “home run”. The FDA chose to accept Ionis’ expansion bid under the priority review track in February, which CEO Dr. Brett Monier said was “an important step toward our goal of delivering the first-ever therapy shown to reduce the risk of potentially life-threatening acute pancreatitis attacks in sHTG patients.”
“We believe this is an unprecedented and historic achievement in the field of lipidology, where the quest to reduce the risk of acute pancreatitis in sHTG has been ongoing for nearly 50 years,” added Sam Tsimikas, MD, Ionis’ global head of cardiovascular development, during a webcast after the lower trial results in September.
Severe hypertriglyceridemia is characterized by very high triglycerides and an increased risk of acute pancreatitis and hospitalization. Tringolza is designed to reduce the body’s production of apoC-III, a triglyceride metabolism regulatory protein, and Ionis is targeting a U.S. patient population of 3 million people, including 1 million sHTG patients considered high-risk.
Ionis focuses on the largely untapped commercial treatment market for sHTG and predicts that Tringorza could have peak sales of more than $2 billion for both indications combined. Monia said in a presentation at the time that the company doubled its peak revenue forecast for the drug in January based on research suggesting a significant increase in expected sales compared to the company’s previous expectations.
FCS’ Tirungolza marks the first standalone product launch for Ionis, which has licensed medicines to development partners for many years. After being approved by the FDA the previous year, the drug generated $108 million in sales in 2025.
Arrowhead remains several steps behind Ionis in terms of regulation, and late last year its Redenpro received breakthrough therapy designation in sHTG. Arrowhead’s agreement to FCS was announced a year after Tringorza crossed the FDA finish line with the same symptoms and after a bitter legal battle in which Arrowhead accused Ionis of copying its mRNA technology to make Redenpro.
